A Novel SCN9A Gene Mutation in a Patient with Carbamazepine-Resistant Paroxysmal Extreme Pain Disorder
Received Date: Nov 18, 2015 / Accepted Date: Dec 08, 2015 / Published Date: Dec 16, 2015
Abstract
Paroxysmal extreme pain disorder is an autosomal dominant disorder caused by mutation of the SCN9A gene. In most cases, the pain is relieved by carbamazepine. We report on a novel SCN9A mutation associated with carbamazepine-resistant. The proband was a 7-month-old child who suffered from typical attacks from birth onwards. Sequencing of SCN9A revealed a heterozygous c.4880T>G substitution. Identification of this novel mutation and characterization of the associated carbamazepine-resistant phenotype may facilitate diagnosis and drug development.
Keywords: Nerve pain; Mutation; Paroxysmal extreme pain disorder
Citation: Sablonnière B, Huin V, Cuvellier J, Genet A, Dhaenens C, et al. (2015) A Novel SCN9A Gene Mutation in a Patient with Carbamazepine-Resistant Paroxysmal Extreme Pain Disorder. Neonat Pediatr Med 1: S1004. Doi: 10.4172/2572-4983.1000S1004
Copyright: © 2015 Sablonniere B, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share This Article
Recommended Conferences
9th World Conference on Nursing Education & Nursing Practice
Toronto, Canada
42nd Global Conference on Nursing Care & Patient Safety
Toronto, CanadaRecommended Journals
Open Access Journals
Article Tools
Article Usage
- Total views: 3293
- [From(publication date): 0-2015 - Nov 29, 2024]
- Breakdown by view type
- HTML page views: 2668
- PDF downloads: 625